참고문헌
- Bang SM, Heo DS, Lee KH, et al (2000). Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma. Cancer, 89, 2521-6. https://doi.org/10.1002/1097-0142(20001215)89:12<2521::AID-CNCR2>3.0.CO;2-F
- Bonadonna G, Valagussa P, Moliterni A, et al (1995). Adjuvant cyclophosphamide, methotrexate, and fluorouracil in nodepositive breast cancer: the results of 20 years of follow-up. N Engl J Med, 332, 901-6. https://doi.org/10.1056/NEJM199504063321401
- Bonadonna G, Zambetti M, Moliterni A, et al (2004). Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer. J Clin Oncol, 22, 1614-20. https://doi.org/10.1200/JCO.2004.07.190
- Bontenbal M, Creemers GJ, Braun HJ, et al (2005). Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as firstline chemotherapy in patients with metastatic breast cancer: results of a dutch community setting trial for the clinical trial group of the comprehensive cancer centre. J Clin Oncol, 23, 7081-8. https://doi.org/10.1200/JCO.2005.06.236
- Citron ML, Berry DA, Cirrincione C, et al (2003). Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol, 21, 1431-9. https://doi.org/10.1200/JCO.2003.09.081
- Early Breast Cancer Trialists' Collaborative Group (1998). Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet, 352, 930-42. https://doi.org/10.1016/S0140-6736(98)03301-7
- Early Breast Cancer Trialists' Collaborative Group (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 365, 1687-717. https://doi.org/10.1016/S0140-6736(05)66544-0
- Early Breast Cancer Trialists' Collaborative G, Peto R, Davies C, et al (2012). Comparisons between different polychemotherapy regimens for early breast cancer: metaanalyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet, 379, 432-44. https://doi.org/10.1016/S0140-6736(11)61625-5
- Eiermann W, Pienkowski T, Crown J, et al (2011). Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol, 29, 3877-84. https://doi.org/10.1200/JCO.2010.28.5437
- Ellis GK, Livingston RB, Gralow JR, et al (2002). Dose-dense anthracycline-based chemotherapy for node-positive breast cancer. J Clin Oncol, 20, 3637-43. https://doi.org/10.1200/JCO.2002.12.113
- Gogas H, Dafni U, Karina M, et al (2012). Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. Breast Cancer Res Treat, 132, 609-19. https://doi.org/10.1007/s10549-011-1913-4
- Gogia A, Raina V, Deo SV, et al (2014). Taxane and anthracycline based neoadjuvant chemotherapy for locally advanced breast cancer: institutional experience. Asian Pac J Cancer Prev, 15, 1989-92. https://doi.org/10.7314/APJCP.2014.15.5.1989
- Henderson IC, Berry DA, Demetri GD, et al (2003). Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol, 21, 976-83. https://doi.org/10.1200/JCO.2003.02.063
- Jones RL, Walsh G, Ashley S, et al (2009). A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer. Br J Cancer, 100, 305-10. https://doi.org/10.1038/sj.bjc.6604862
- Kimura M, Tominaga T, Takatsuka Y, et al (2010). Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan. Breast Cancer, 17, 190-8. https://doi.org/10.1007/s12282-009-0132-x
- Levine MN, Bramwell VH, Pritchard KI, et al (1998). Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 16, 2651-8. https://doi.org/10.1200/JCO.1998.16.8.2651
- Mackey JR, Martin M, Pienkowski T, et al (2013). Adjuvant docetaxel, doxorubicin, and cyclophosphamide in nodepositive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol, 14, 72-80. https://doi.org/10.1016/S1470-2045(12)70525-9
- Martin M, Segui MA, Anton A, et al (2010). Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med, 363, 2200-10. https://doi.org/10.1056/NEJMoa0910320
- Martin M, Villar A, Sole-Calvo A, et al (2003). Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. Ann Oncol, 14, 833-42. https://doi.org/10.1093/annonc/mdg260
- Morris PG, Dickler M, McArthur HL, et al (2009). Dosedense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. J Clin Oncol, 27, 6117-23. https://doi.org/10.1200/JCO.2008.20.2952
- Nabholtz JM, Falkson C, Campos D, et al (2003). Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol, 21, 968-75. https://doi.org/10.1200/JCO.2003.04.040
- Norton L, Simon R (1986). The Norton-Simon hypothesis revisited. Cancer Treat Rep, 70, 163-9.
- Ozdemir N, Aksoy S, Zengin N, et al (2012). Taxanes in the adjuvant treatment of node-negative breast cancer patients. J BUON, 17, 27-32.
- Sakr H, Hamed RH, Anter AH, et al (2013). Sequential docetaxel as adjuvant chemotherapy for node-positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Med Oncol, 30, 457. https://doi.org/10.1007/s12032-013-0457-3
- Senkus E, Kyriakides S, Penault-Llorca F, et al (2013). Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 24, 7-23.
- Siegel R, Ma J, Zou Z, et al (2014). Cancer statistics, 2014. CA Cancer J Clin, 64, 9-29. https://doi.org/10.3322/caac.21208
- Slamon DJ, Clark GM, Wong SG, et al (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-82. https://doi.org/10.1126/science.3798106
- Sparano JA, Wang M, Martino S, et al (2005). Phase III study of doxorubicin cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: results of North American Breast Cancer Intergroup Trial E1199. Breast Cancer Res Treat, 94, 516.
- Sparano JA, Wang M, Martino S, et al (2008). Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med, 358, 1663-71. https://doi.org/10.1056/NEJMoa0707056
- Swain SM, Tang G, Geyer CE, et al (2013). Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. J Clin Oncol, 31, 3197-204. https://doi.org/10.1200/JCO.2012.48.1275
- Theriault RL, Carlson RW, Allred C, et al (2013). Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw, 11, 753-60. https://doi.org/10.6004/jnccn.2013.0098
- Venturini M, Del Mastro L, Aitini E, et al (2005). Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst, 97, 1724-33. https://doi.org/10.1093/jnci/dji398
피인용 문헌
- Prognostic Value of Chemotherapy-Induced Amenorrhea in Breast Cancer: a Meta-Analysis vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5939